Comparison
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between 3 Methylcrotonyl Coa Carboxylase 2 Deficiency and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
A rare metabolic disorder affecting leucine breakdown. Infants may show developmental delay, seizures, and metabolic crises. Treatment involves biotin supplements and dietary protein restriction.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
0-null
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
metabolic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
metabolic
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
3-methylcrotonyl-coa-carboxylase-2-deficiency-C1859499 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Metabolic crisis | Infants may have crises linked to impaired leucine breakdown. | Metabolic crises are not described in the supplied data. | High |
| Developmental delay | May occur, sometimes with seizures. | Developmental delay and neurological features may occur. | Low |
| Kidney involvement | Not described in the supplied data. | Potential kidney involvement is reported. | Moderate |
When to favor each condition
Choose 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 when
Infant with suspected metabolic decompensation
Leucine-pathway dysfunction and crises fit the metabolic description.
Moderate
Abnormal leucine-related metabolic testing
Supports suspicion but does not by itself confirm the diagnosis.
Moderate
MCCC2-related genetic finding
A clinician-confirmed pathogenic finding would favor this diagnosis.
High
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Confirmed recurrent 17q12 deletion
The chromosomal deletion defines this congenital syndrome.
High
Developmental and neurological features with renal concern
This combination better matches the supplied syndrome description.
Moderate
No evidence of leucine-related metabolic crisis
Absence of that pattern makes the metabolic disorder less likely, but does not exclude it.
Low
How key tests differ
| Test | 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Metabolic studies | May suggest disordered leucine metabolism; exact cutoffs are not supplied. | No characteristic metabolic abnormality is established here. | An abnormal result is not a diagnosis and needs specialist review. |
| Genetic testing | MCCC2-related variant testing may be considered. | Chromosomal testing may identify a 17q12 deletion. | The genetic target differs; interpretation requires a qualified clinician. |
| Renal evaluation | No expected renal finding is established from supplied data. | Monitoring may be used because kidney involvement is possible. | Imaging or laboratory abnormalities require clinical correlation. |
Prognosis comparison
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
- Outcome
- Classified as severe, but individual outcome is not established.
- Factors
- Metabolic crises, developmental problems, and treatment response may matter.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- Classified as moderate, with variable developmental and possible renal effects.
- Factors
- Extent of developmental, neurological, and kidney involvement may matter.
Time frame: Both are chronic; no reliable time-specific prognosis is supplied.
Diagnosis confirmation, complications, and individualized care influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Metabolic decompensation | Possible and potentially serious during illness or catabolism. Not established from the supplied description. Emergency assessment is appropriate for concerning symptoms. |
| Neurological complications | Seizures and developmental delay may occur. Neurological features and developmental delay may occur. Causes and severity can differ and are not fully defined here. |
| Renal complications | Not described in the supplied source. Potential kidney involvement warrants monitoring. The frequency and severity are not established here. |
Patient education highlights
- HighDifferent causes
One affects leucine metabolism; the other results from a chromosome 17q12 deletion.
- HighWhen to seek care
Seek urgent care for poor feeding, lethargy, seizures, or other acute deterioration.
- MediumFollow-up
Management may include diet or biotin discussion for the metabolic disorder and supportive monitoring for the deletion syndrome.